Company / FCF Margin
Immix Biopharma, Inc. FCF Margin History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-78.9%
FY2025
5-year range
-78.9% / -37.3%
FY2023-FY2025
Trend
-38.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -37.3% to -78.9% over the past 2 years.
Based on SEC 10-K filings.
-78.9% in FY2025.
Declined from -37.3% to -78.9% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, fcf margin decreased 38.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -78.9% | -38.1% |
| FY2024 | -57.1% | -53.1% |
| FY2023 | -37.3% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026